Trial
NCT06735079
A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD)
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
MGGM LLC
Collaborators
—
Condition
Major Depressive Disorder (MDD)
Intervention
REL1017 (esmethadone HCI) (active drug)
Why stopped
The study was withdrawn based on business-related matters and there are no new safety concerns related to the trial. No patients were enrolled.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-07